/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

NAUTILUS BIOTECHNOLOGY INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.07 0.0505(5.05%) NAUT at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 1.93
Highest Today 2.08
Today’s Open 1.96
Prev. Close 1.98
52 Week High 2.54
52 Week Low 0.62
Day’s Range: Low 1.93 High 2.08
52-Week Range: Low 0.62 High 2.54
1 day return -
1 Week return -8.0
1 month return +30.18
3 month return +219.64
6 month return +168.09
1 year return -7.17
3 year return +16.94
5 year return -80.58
10 year return -

Institutional Holdings

Perceptive Advisors LLC 9.97

Cercano Management LLC 5.68

Madrona Venture Group, LLC 4.77

Vanguard Group Inc 1.97

Comprehensive Financial Management LLC 1.75

Vanguard Total Stock Mkt Idx Inv 1.35

Amazon.com Inc 1.15

Clarius Group, LLC 0.84

Millennium Management LLC 0.84

Tikvah Management LLC 0.58

BlackRock Inc 0.50

Botty Investors LLC 0.49

Renaissance Technologies Corp 0.49

Geode Capital Management, LLC 0.44

Dimensional Fund Advisors, Inc. 0.44

Vanguard Institutional Extnd Mkt Idx Tr 0.36

CI Private Wealth LLC 0.34

Goldman Sachs Group Inc 0.25

Jane Street Group LLC 0.23

Sentinel Trust CO Lba 0.22

Jacobs Levy Equity Management, Inc. 0.20

Fidelity Extended Market Index 0.20

Alyeska Investment Group, L.P. 0.20

DFA US Targeted Value I 0.13

Bridgeway Ultra-Small Company Market 0.10

Dimensional US Targeted Value ETF 0.09

Extended Equity Market Fund K 0.07

Fidelity Total Market Index 0.07

DFA US Micro Cap I 0.06

Dimensional US Core Equity 2 ETF 0.06

Fidelity Nasdaq Composite Index 0.05

Fidelity Series Total Market Index 0.05

Goldman Sachs Absolute Ret Trckr Instl 0.05

Spartan Extended Market Index Pool F 0.04

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.04

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Dimensional Global Trgtd Value USD Acc 0.04

NT Ext Equity Mkt Idx Fd - NL 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

Market Status

Strong Buy: 2

Buy: 0

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 250.08 M

PB Ratio 1.6802

PE Ratio 0.0

Enterprise Value 179.76 M

Total Assets 242.74 M

Volume 83167

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-60060000 -60.1M, FY22:-63740000 -63.7M, FY21:-50315000 -50.3M, FY20:-15619000 -15.6M, FY19:2578622 2.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1619000 -1.6M, Q2/2025:-1633000 -1.6M, Q1/2025:-1625000 -1.6M, Q3/2024:-1612000 -1.6M, Q2/2024:-1597000 -1.6M

Quarterly Net worth Q3/2025:-13574000 -13.6M, Q2/2025:-15033000 -15.0M, Q1/2025:-16613000 -16.6M, Q3/2024:-16446000 -16.4M, Q2/2024:-18010000 -18.0M

Fund house & investment objective

Company Information Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Organisation Biotechnology

Employees 124

Industry Biotechnology

CEO Mr. Sujal M. Patel

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow